| Issue Date | Title | Author(s) | Relation | scopus | WOS | Fulltext/Archive link |
| 2017 | Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients | Lee, MH; Huang, CF; Lai, HC; Lin, CY; Dai, CY; Liu, CJ; Wang, JH; Huang, JF; Su, WP; Yang, HC; Kee, KM; Yeh, ML; Chuang, PH; Hsu, SJ; Huang, CI; Kao, JT; Chen, CC; Chen, SH; Jeng, WJ; Yang, HI; Yuan, Y; Lu, SN; Sheen, IS; Liu, CH; Peng, CY; Kao, JH; Yu, ML; Chuang, WL; Chen, CJ | Scientific reports 7, 3718 | | | |
| 2021 | Development and validation of a risk score for liver cirrhosis prediction in untreated and treated chronic hepatitis B | Le, AK; Yang, HI ; Yeh, ML; Jin, M; Trinh, HN; Henry, L; Liu, A; Zhang, JQ; Li, J; Wong, C; Wong, C; Cheung, R; Yu, ML; Nguyen, MH | JOURNAL OF INFECTIOUS DISEASES 223(1), 139-146 | | | |
| 2019 | Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. | Huang, CF; Iio, E; Jun, DW; Ogawa, E; Toyoda, H; Hsu, YC; Haga, H; Iwane, S; Enomoto, M; Lee, DH; Wong, G; Liu, CH; Tada, T; Chuang, WL; Cheung, R; Hayashi, J; Tseng, CH; Yasuda, S; Tran, S; Kam, L; Henry, L; Jeong, JY; Nomura, H; Park, SH; Nakamuta, M; Huang, JF; Tai, CM; Lo, GH; Lee, MH; Yang, HI ; Kao, JH; Tamori, A; Eguchi, Y; Ueno, Y; Furusyo, N; Tanaka, Y; Yu, ML; Nguyen, MH | Hepatology international 13, 587-598 | | | |
| 2019 | HCV Cure Rates are Reduced in Patients with Active but not Inactive Hepatocellular Carcinoma- A Practice Implication. | Ogawa, E; Toyoda, H; Iio, E; Jun, DW; Huang, CF; Enomoto, M; Hsu, YC; Haga, H; Iwane, S; Wong, G; Lee, DH; Tada, T; Liu, CH; Chuang, WL; Hayashi, J; Cheung, R; Yasuda, S; Tseng, CH; Takahashi, H; Tran, S; Yeo, YH; Henry, L; Barnett, SD; Nomura, H; Nakamuta, M; Dai, CY; Huang, JF; Yang, HI ; Lee, MH; Jung Jun, M; Kao, JH; Eguchi, Y; Ueno, Y; Tamori, A; Furusyo, N; Yu, ML; Tanaka, Y; Nguyen, MH; Ahn, SB; Azuma, K; Dohmen, K; Yoon Jeong, J; Jung, JH; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Ooho, A; Park, SH; Satoh, T; Shimoda, S; Song, DS; Takahashi, K; Yeh, ML; Yoon, EL | Clinical Infectious Diseases, ciz1160 | | | |
| 2022 | Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine | Park, J; Le, AK; Tseng, TC; Yeh, ML; Jun, DW; Trinh, H; Wong, GLH; Chen, CH; Peng, CY; Kim, SE; Oh, H; Kwak, MS; Cheung, KS; Toyoda, H; Hsu, YC; Jeong, JY; Yoon, EL; Ungtrakul, T; Zhang, J; Xie, Q; Ahn, SB; Enomoto, M; Shim, JJ; Cunningham, C; Jeong, SW; Cho, YK; Ogawa, E; Huang, R; Lee, DH; Takahashi, H; Tsai, PC; Huang, CF; Dai, CY; Tseng, CH; Yasuda, S; Kozuka, R; Li, J; Wong, C; Wong, CC; Zhao, C; Hoang, J; Eguchi, Y; Wu, C; Tanaka, Y; Gane, E; Tanwandee, T; Cheung, R; Yuen, MF; Lee, HS; Yu, ML; Kao, JH; Yang, HI ; Nguyen, MH | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20(4), 874-885.e4 | | | |
| 2020 | Real-world Effectiveness from the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Oral Antiviral Therapy. | Yang, HI ; Yeh, ML; Wong, GL; Peng, CY; Chen, CH; Trinh, HN; Cheung, KS; Xie, Q; Su, TH; Kozuka, R; Lee, DH; Ogawa, E; Zhao, C; Ning, HB; Huang, R; Li, J; Zhang, JQ; Ide, T; Xing, H; Iwane, S; Takahashi, H; Wong, C; Wong, C; Lin, CH; Hoang, J; le, A; Henry, L; Toyoda, H; Ueno, Y; Gane, EJ; Eguchi, Y; Kurosaki, M; Wu, C; Liu, C; Shang, J; Furusyo, N; Enomoto, M; Kao, JH; Yuen, MF; Yu, ML; Nguyen, MH | The Journal of infectious diseases 221(3), 389-399 | | | |
| 2017 | Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance | Huang, CF; Yeh, ML; Huang, CI; Lin, YJ; Tsai, PC; Lin, ZY; Chan, SY; Chen, SC; Yang, HI; Huang, JF; Lu, SN; Dai, CY; Jen, CL; Yuan, Y; L'Italien, G; Wang, LY; Lee, MH; Yu, ML; Chuang, WL; Chen, CJ | Oncotarget 8(27), 43925-43933 | | | |
| 2021 | Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines | Teng, W; Chang, TT; Yang, HI ; Peng, CY; Su, CW; Su, TH; Hu, TH; Yu, ML; Yang, HC; Wu, JC | Hepatology international 15, 1421-1430 | | | |
